Showing 7091-7100 of 8649 results for "".
- Vabysmo Receives CHMP Recommendation for RVO Indicationhttps://modernod.com/news/roches-vabysmo-gets-chmp-recommendation-for-rvo-indication/2482337/Roche announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the extension of Vabysmo (faricimab) marketing authorization to include the treatment of visual impairment caused by macular edema secondary to retin
- Rayner Closes Recruitment for IDE for RayOne EMV Toric IOLshttps://modernod.com/news/rayner-closes-recruitment-for-ide-for-rayone-emv-toric-iols/2482332/Rayner announced that it has closed recruitment in the investigational device exemption (IDE) study for its EMV Toric IOL in the US. The study will ultimately enable the introduction of the RayOne EMV Toric lens for use in the US. Developed in collaboration with Professor
- Researchers Examine Potential Immunotherapy Option for Diabetic Retinopathyhttps://modernod.com/news/researchers-examine-potential-immunotherapy-option-for-diabetic-retinopathy/2482327/Researchers at the University of Oklahoma Health Sciences and Memorial Sloan Kettering (MSK) Cancer Center are studying a new treatment in which anti-ceramide immunotherapy can address the root cause of diabetic retinopathy and stop progression toward blindness at an earlier stage
- Ocugen Doses First Patient in Phase 3 Clinical Trial for OCU400 Gene Therapy for RPhttps://modernod.com/news/ocugen-doses-first-patient-in-phase-3-clinical-trial-for-ocu400-gene-therapy-for-retinitis-pigmentosa/2482326/Ocugen announced that the first patient has been dosed in its phase 3 liMeliGhT clinical trial for OCU400, a modifier gene therapy product candidate being developed for retinitis pigmentosa (RP). “Each clinical milestone achieved by OCU400 brings us closer to providing a one-
- Harrow Provides Triesence Relaunch Updatehttps://modernod.com/news/harrow-provides-triesence-relaunch-update/2482325/Harrow has announced the manufacture of the first of three commercial-scale process performance qualification (PPQ) batches of Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is FDA‑approved for visualization during vitrec
- Neurotech Receives Priority Review of BLA for NT-501 as a Treatment for Macular Telangiectasia Type 2 (MacTel)https://modernod.com/news/neurotech-receives-priority-review-of-biologics-license-application-bla-for-nt-501-as-a-treatment-for-macular-telangiectasia-type-2-mactel/2482324/The FDA has granted priority review of Neurotech Pharmaceuticals's biologic license application (BLA) for NT-501 (revakinagene taroretcel), an investigational encapsulated cell therapy for the treatment of Macular Telangiectasia Type 2 (MacTel). The designation m
- EyeCare Partners Names New Members to Executive Leadership Teamhttps://modernod.com/news/eyecare-partners-names-new-members-to-executive-leadership-team/2482321/EyeCare Partners announced new additions and changes to its executive leadership team. Appointments and changes are: Andrew Hardesty has been promoted to the new role of Chief Program Officer, effective immediately. This role oversees and lea
- Opus Genetics Receives $1.7 Million in Funding from the Foundation Fighting Blindness to Support Two Preclinical Programshttps://modernod.com/news/opus-genetics-receives-17-million-in-funding-from-the-foundation-fighting-blindness-to-support-two-preclinical-programs/2482320/Gene therapy company Opus Genetics announced it has received $1.7 million in project-based funding from the Foundation Fighting Blindness to help advance two preclinical candidate programs. “Opus is immensely grateful for the generous support from the Foundation Fighting Blin
- Skye Fails Phase 2 Glaucoma Trial; Shifts Focus to Obesityhttps://modernod.com/news/skye-fails-phase-2-glaucoma-trial-shifts-focus-to-obesity/2482317/Skye Bioscience announced that its phase 2a clinical trial of SBI-100 ophthalmic emulsion in patients with primary open-angle glaucoma or ocular hypertension did not meet its primary endpoint for lowering IOP. As a result, Skye intends to discontinue clinical development and spendi
- Geoff Tabin, MD, Co-Founder of Global NGO HCP Cureblindness, Steps Into New Rolehttps://modernod.com/news/geoff-tabin-md-co-founder-of-global-ngo-hcp-cureblindness-steps-into-new-role/2482314/Effective immediately, Geoff Tabin, MD, will step down as Board Chair of the global nonprofit HCP Cureblindness (Himalayan Cataract Project), but will maintain an active role on the Board as Medical Director. Long-time HCP volunteer and Board Member, Matt Oliva, MD, will lead HCP into its excitin